Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Avastin Generic Name & Formulations
Legal Class
Rx
General Description
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (4mL, 16mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (F1t-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
Avastin Indications
Indications
Metastatic renal cell carcinoma (mRCC) in combination with interferon alfa.
Avastin Dosage and Administration
Adult
Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 10mg/kg every 2 weeks with interferon alfa.
Children
<18yrs: not established.
Administration
Administer only as an IV infusion. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Nursing Considerations
Administer only as an IV infusion. Avoid administering or mixing with dextrose solution. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Avastin Contraindications
Not Applicable
Avastin Boxed Warnings
Not Applicable
Avastin Warnings/Precautions
Warnings/Precautions
Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. HCC patients: assess for presence of varices within 6 months of therapy initiation. Avoid in ovarian cancer if evidence of recto-sigmoid involvement by pelvic exam, bowel involvement on CT scan, or symptoms of bowel obstruction. Discontinue if GI perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula formation involving any organ. Wound healing complications: withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing. Discontinue if necrotizing fasciitis, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, Grade 4 venous thromboembolic event (including pulmonary embolism), hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after the last dose).
Avastin Pharmacokinetics
Elimination
Half-life: ~20 days.
Avastin Interactions
Interactions
Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).
Avastin Adverse Reactions
Adverse Reactions
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound healing complications, necrotizing fasciitis, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.
Avastin Clinical Trials
See Literature
Avastin Note
Not Applicable
Avastin Patient Counseling
See Literature
Avastin Generic Name & Formulations
Legal Class
Rx
General Description
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (4mL, 16mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (F1t-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
Avastin Indications
Indications
Recurrent glioblastoma in adults.
Avastin Dosage and Administration
Adult
Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 10mg/kg every 2 weeks.
Children
<18yrs: not established.
Administration
Administer only as an IV infusion. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Nursing Considerations
Administer only as an IV infusion. Avoid administering or mixing with dextrose solution. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Avastin Contraindications
Not Applicable
Avastin Boxed Warnings
Not Applicable
Avastin Warnings/Precautions
Warnings/Precautions
Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. HCC patients: assess for presence of varices within 6 months of therapy initiation. Avoid in ovarian cancer if evidence of recto-sigmoid involvement by pelvic exam, bowel involvement on CT scan, or symptoms of bowel obstruction. Discontinue if GI perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula formation involving any organ. Wound healing complications: withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing. Discontinue if necrotizing fasciitis, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, Grade 4 venous thromboembolic event (including pulmonary embolism), hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after the last dose).
Avastin Pharmacokinetics
Elimination
Half-life: ~20 days.
Avastin Interactions
Interactions
Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).
Avastin Adverse Reactions
Adverse Reactions
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound healing complications, necrotizing fasciitis, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.
Avastin Clinical Trials
See Literature
Avastin Note
Not Applicable
Avastin Patient Counseling
See Literature
Avastin Generic Name & Formulations
Legal Class
Rx
General Description
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (4mL, 16mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (F1t-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
Avastin Indications
Indications
Metastatic colorectal carcinoma (mCRC), in combination with 5-FU-based chemotherapy for first- or second-line treatment; or in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based therapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Limitations of use: not for adjuvant treatment of colon cancer. In combination with atezolizumab for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy.
Avastin Dosage and Administration
Adult
Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. mCRC: 5mg/kg (when used with bolus-IFL) or 10mg/kg (when used with FOLFOX-4) once every 2 weeks until disease progression detected; 5mg/kg every 2 weeks or 7.5mg/kg every 3 weeks (when used with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based therapy). HCC: 15mg/kg (after administration of atezolizumab 1200mg) every 3 weeks until disease progression or unacceptable toxicity.
Children
<18yrs: not established.
Administration
Administer only as an IV infusion. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Nursing Considerations
Administer only as an IV infusion. Avoid administering or mixing with dextrose solution. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Avastin Contraindications
Not Applicable
Avastin Boxed Warnings
Not Applicable
Avastin Warnings/Precautions
Warnings/Precautions
Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. HCC patients: assess for presence of varices within 6 months of therapy initiation. Avoid in ovarian cancer if evidence of recto-sigmoid involvement by pelvic exam, bowel involvement on CT scan, or symptoms of bowel obstruction. Discontinue if GI perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula formation involving any organ. Wound healing complications: withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing. Discontinue if necrotizing fasciitis, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, Grade 4 venous thromboembolic event (including pulmonary embolism), hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after the last dose).
Avastin Pharmacokinetics
Elimination
Half-life: ~20 days.
Avastin Interactions
Interactions
Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).
Avastin Adverse Reactions
Adverse Reactions
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound healing complications, necrotizing fasciitis, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.
Avastin Clinical Trials
See Literature
Avastin Note
Not Applicable
Avastin Patient Counseling
See Literature
Avastin Generic Name & Formulations
Legal Class
Rx
General Description
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (4mL, 16mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (F1t-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
Avastin Indications
Indications
Persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel/cisplatin, or paclitaxel/topotecan. Stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer after initial surgical resection, in combination with carboplatin/paclitaxel, followed by Avastin as a single agent. Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (platinum-resistant): in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan in patients who received no more than 2 prior chemotherapy regimens; (platinum-sensitive): in combination with carboplatin/paclitaxel or carboplatin/gemcitabine, followed by Avastin as a single agent.
Avastin Dosage and Administration
Adult
Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. Cervical cancer: 15mg/kg every 3 weeks with either paclitaxel/cisplatin, or paclitaxel/topotecan. Stage III/IV disease after initial surgical resection: 15mg/kg every 3 weeks with carboplatin/paclitaxel for up to 6 cycles; followed by Avastin 15mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs first. Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (platinum-resistant): 10mg/kg every 2 weeks with either paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or, 15mg/kg every 3 weeks with topotecan (every 3 weeks); (platinum-sensitive): 15mg/kg every 3 weeks with carboplatin/paclitaxel for 6 to 8 cycles or carboplatin/gemcitabine for 6 to 10 cycles; followed by Avastin 15mg/kg every 3 weeks as a single agent until disease progression.
Children
<18yrs: not established.
Administration
Administer only as an IV infusion. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Nursing Considerations
Administer only as an IV infusion. Avoid administering or mixing with dextrose solution. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Avastin Contraindications
Not Applicable
Avastin Boxed Warnings
Not Applicable
Avastin Warnings/Precautions
Warnings/Precautions
Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. HCC patients: assess for presence of varices within 6 months of therapy initiation. Avoid in ovarian cancer if evidence of recto-sigmoid involvement by pelvic exam, bowel involvement on CT scan, or symptoms of bowel obstruction. Discontinue if GI perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula formation involving any organ. Wound healing complications: withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing. Discontinue if necrotizing fasciitis, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, Grade 4 venous thromboembolic event (including pulmonary embolism), hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after the last dose).
Avastin Pharmacokinetics
Elimination
Half-life: ~20 days.
Avastin Interactions
Interactions
Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).
Avastin Adverse Reactions
Adverse Reactions
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound healing complications, necrotizing fasciitis, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.
Avastin Clinical Trials
See Literature
Avastin Note
Not Applicable
Avastin Patient Counseling
See Literature
Avastin Generic Name & Formulations
Legal Class
Rx
General Description
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (4mL, 16mL)—1
Manufacturer
Generic Availability
NO
Mechanism of Action
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (F1t-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
Avastin Indications
Indications
First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel.
Avastin Dosage and Administration
Adult
Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 15mg/kg every 3 weeks with carboplatin/paclitaxel.
Children
<18yrs: not established.
Administration
Administer only as an IV infusion. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Nursing Considerations
Administer only as an IV infusion. Avoid administering or mixing with dextrose solution. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. Withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing.
Avastin Contraindications
Not Applicable
Avastin Boxed Warnings
Not Applicable
Avastin Warnings/Precautions
Warnings/Precautions
Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. HCC patients: assess for presence of varices within 6 months of therapy initiation. Avoid in ovarian cancer if evidence of recto-sigmoid involvement by pelvic exam, bowel involvement on CT scan, or symptoms of bowel obstruction. Discontinue if GI perforation, tracheoesophageal fistula, Grade 4 fistula, or fistula formation involving any organ. Wound healing complications: withhold for ≥28 days prior to elective surgery; do not give for ≥28 days after major surgery and until adequate healing. Discontinue if necrotizing fasciitis, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, Grade 4 venous thromboembolic event (including pulmonary embolism), hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after the last dose).
Avastin Pharmacokinetics
Elimination
Half-life: ~20 days.
Avastin Interactions
Interactions
Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).
Avastin Adverse Reactions
Adverse Reactions
Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound healing complications, necrotizing fasciitis, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.
Avastin Clinical Trials
See Literature
Avastin Note
Not Applicable
Avastin Patient Counseling
See Literature
